Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Exon 20 Insertion Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05967689
What this trial is testing

Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Who this might be right for
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc. 220
Early research (Phase 1)Active Not RecruitingNCT05364073
What this trial is testing

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc. 160
Early research (Phase 1)Study completedNCT06001671
What this trial is testing

Antitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLC

Who this might be right for
NSCLC
Hunan Province Tumor Hospital 23
Large-scale testing (Phase 3)Active Not RecruitingNCT04538664
What this trial is testing

Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 308
Testing effectiveness (Phase 2)Looking for participantsNCT06514027
What this trial is testing

Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

Who this might be right for
Non Small Cell Lung Cancer
BeBetter Med Inc 30
Not applicableStudy completedNCT05419700
What this trial is testing

A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 Insertion

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Takeda 76
Testing effectiveness (Phase 2)Ended earlyNCT04402008
What this trial is testing

Study of Poziotinib in Japanese Patients With NSCLC

Who this might be right for
NSCLC
Spectrum Pharmaceuticals, Inc 42
Testing effectiveness (Phase 2)UnknownNCT05435274
What this trial is testing

Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non-Small-Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 380
Early research (Phase 1)Looking for participantsNCT06816992
What this trial is testing

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

Who this might be right for
Solid TumorsEGFR Exon 20 Insertion MutationsNSCLC+1 more
ORIC Pharmaceuticals 76
Not applicableLooking for participantsNCT06418412
What this trial is testing

A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC

Who this might be right for
Advanced EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer
National Cancer Centre, Singapore 600
Testing effectiveness (Phase 2)Looking for participantsNCT06192849
What this trial is testing

To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Who this might be right for
Non Small Cell Lung CancerEGFR Exon 20 Insertion Mutation
Juan LI, MD 20
Not applicableLooking for participantsNCT06247826
What this trial is testing

Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion

Who this might be right for
Non-small Cell Lung CancerEGFR Exon 20 Insertion Mutation
Groupe Francais De Pneumo-Cancerologie 30
Testing effectiveness (Phase 2)UnknownNCT05132777
What this trial is testing

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung CancerEGFR Exon20 Insertion Mutations
Shanghai JMT-Bio Inc. 155
Testing effectiveness (Phase 2)Active Not RecruitingNCT05712902
What this trial is testing

Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)

Who this might be right for
Non-Small Cell Lung Cancer
Dizal Pharmaceuticals 104
Testing effectiveness (Phase 2)Active Not RecruitingNCT05466149
What this trial is testing

Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion

Who this might be right for
NSCLC
Allist Pharmaceuticals, Inc. 100
Testing effectiveness (Phase 2)Ended earlyNCT03744715
What this trial is testing

Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib

Who this might be right for
NSCLCBreast Cancer
Spectrum Pharmaceuticals, Inc 7
Not applicableAvailableNCT07601399
What this trial is testing

An EAP Treatment Protocol of Zipalertinib

Who this might be right for
Non-Small Cell Lung Cancer
Taiho Oncology, Inc.
Large-scale testing (Phase 3)Active Not RecruitingNCT05973773
What this trial is testing

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

Who this might be right for
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Taiho Oncology, Inc. 285
Testing effectiveness (Phase 2)Ended earlyNCT03318939
What this trial is testing

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Who this might be right for
NSCLC
Spectrum Pharmaceuticals, Inc 648
Testing effectiveness (Phase 2)UnknownNCT05498389
What this trial is testing

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaAdvanced Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8+6 more
Shanghai EpimAb Biotherapeutics Co., Ltd. 115
Next Page